AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating next-generation radioconjugates (RCs) for cancer treatment. This strategic acquisition not only expands AstraZeneca’s capabilities in targeted cancer therapy but also consolidates its research and development footprint in North America. Financial […]
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.’s shareholders have overwhelmingly voted in favor of the proposed acquisition by AstraZeneca. During a special virtual meeting, approximately 80.83% of Fusion’s issued and outstanding shares were represented, with 99.92% of these votes endorsing the acquisition under the terms of a plan of arrangement as […]
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of next-generation radioconjugates (RCs) for cancer therapy. This acquisition is a pivotal step for AstraZeneca in fulfilling its vision to transform cancer care, aiming to substitute conventional treatments such as chemotherapy […]
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals, has announced a landmark exclusive worldwide license agreement with Heidelberg University and Euratom, represented by the European Commission, Joint Research Centre. This pivotal agreement confers upon Fusion the exclusive worldwide rights to develop, manufacture, and commercialize compounds […]
